HYALGAN

This brand name is authorized in Austria, Cyprus, Ecuador, France, Hong Kong SAR China, Lithuania, Poland, Romania, Singapore, Spain, Tunisia.

Active ingredients

The drug HYALGAN contains one active pharmaceutical ingredient (API):

1	Hyaluronate sodium UNII YSE9PPT4TH - HYALURONATE SODIUM
	Read more about Hyaluronate sodium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HYALGAN Solution for injection	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M09AX01	Hyaluronic acid	M Musculo-skeletal system → M09 Other drugs for disorders of the musculo-skeletal system → M09A Other drugs for disorders of the musculo-skeletal system → M09AX Other drugs for disorders of the musculo-skeletal system
Discover more medicines within M09AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1224-MEE-0815
ES	Centro de información online de medicamentos de la AEMPS	262IS14F12, 63006
FR	Base de données publique des médicaments	64052038
HK	Department of Health Drug Office	34494
LT	Valstybinė vaistų kontrolės tarnyba	1012010, 1071036, 1081002, 1091322
PL	Rejestru Produktów Leczniczych	100029680, 100290408, 100376334, 100406443, 100412350, 100415962, 100437194, 100447755
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67509001, W67509002, W67510001
SG	Health Sciences Authority	06242P
TN	Direction de la Pharmacie et du Médicament	7883012